FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease
RegulatoryapprovedCasgevyPositive
AI Analysis
Summary
The FDA issued a supplemental approval for Casgevy (exagamglogene autotemcel), a gene therapy, for treating sickle cell disease and transfusion-dependent β thalassemia in patients aged 2 years and older. This approval expands access to the first gene therapy option for young children with these serious blood disorders.
Outcome Details
Supplemental FDA approval for expanded patient population (ages 2+) with sickle cell disease or transfusion-dependent β thalassemia
Importance:9/10
Sentiment:
0.95
FDA ApprovalGene TherapySickle Cell DiseasePediatricRare DiseaseCRISPR
Related Companies
Read the original article
Published by FDA Press Releases on July 1, 2026 9:29 PM